The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Open accessAbstract
The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor–armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous deletions spanning the CD19 locus and de novo frameshift and missense mutations in exon 2 of CD19 in some relapse samples. However, we also discovered alternatively spliced CD19 mRNA species, including one lacking exon 2. Pull-down/siRNA experiments identified SRSF3 as a splicing factor involved in exon 2 retention, and its levels were lower in relapsed B-ALL. Using genome editing, we demonstrated that exon 2 skipping bypasses exon 2 mutations in B-ALL cells and allows expression of the N-terminally truncated CD19 variant, which fails to trigger killing by CART-19 but partly rescues defects associated with CD19 loss. Thus, this mechanism of resistance is based on a combination of deleterious mutations and ensuing selection for alternatively spliced RNA isoforms. Significance: CART-19 yield 70% response rates in patients with B-ALL, but also produce escape variants. We discovered that the underlying mechanism is the selection for preexisting alternatively spliced CD19 isoforms with the compromised CART-19 epitope. This mechanism suggests a possibility of targeting alternative CD19 ectodomains, which could improve survival of patients with B-cell neoplasms. Cancer Discov; 5(12); 1282–95. ©2015 AACR. See related commentary by Jackson and Brentjens, p. 1238. This article is highlighted in the In This Issue feature, p. 1225
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · cited 1×
“The underlying mechanism notwithstanding, it is becoming clear that alterations in splicing factors are important drivers of hematologic malignancies, as evidenced by the discovery of acquired mutations in the splicing factor gene SF3B1 in chronic lymphocytic leukemia (37) and myelodysplasia (38).”
BackgroundESEfinder: a web resource to identify exonic splicing enhancers
Cartegni, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg616 · Cited by 1,603
A compendium of RNA-binding motifs for decoding gene regulation
Ray, D., Kazan, H., Cook, K. B., Weirauch, M. T., Najafabadi, H. S., Li, X., Gueroussov, S., Albu, M., Zheng, H., Yang, A., et al. (2013) · Nature · doi:10.1038/nature12311 · Cited by 1,480 · cited 1×
“However, the Drosophila homolog of SRSF3, RBP-1, is known to bind to the [A/T] CAAC[A/G] hexamer (23).”
BackgroundMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Messenger-RNA-binding proteins and the messages they carry
Dreyfuss, G., Kim, V. N., & Kataoka, N. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm760 · Cited by 1,469
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“Similarly, in the realm of solid tumors, BRAFV600E splicing variants lacking the RAS-binding domain were found in one third of melanomas with acquired resistance to vemurafenib (39).”
BackgroundAutomatic and Quantitative Measurement of Protein-Protein Colocalization in Live Cells
Costes, S. V., Daelemans, D., Cho, E. H., Dobbin, Z., Pavlakis, G., & Lockett, S. (2004) · Biophysical Journal · doi:10.1529/biophysj.103.038422 · Cited by 1,424
Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics
Maquat, L. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1310 · Cited by 1,214
Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez-Trillos, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 996
Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice
Rickert, R. C., Rajewsky, K., & Roes, J. (1995) · Nature · doi:10.1038/376352a0 · Cited by 664
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Benson, D. A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh045 · Cited by 492
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Self-citationRegulation of Alternative Splicing Through Coupling with Transcription and Chromatin Structure
Naftelberg, S., Schor, I. E., Ast, G., & Kornblihtt, A. R. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034242 · Cited by 448
CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency
van Zelm, M. C., Smet, J., Adams, B., Mascart, F., Schandené, L., Janssen, F., Ferster, A., Kuo, C.-C., Levy, S., van Dongen, J. J. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39748 · Cited by 381
Depoil, D., Fleire, S., Treanor, B. L., Weber, M., Harwood, N. E., Marchbank, K. L., Tybulewicz, V. L. J., & Batista, F. D. (2008) · Nature Immunology · doi:10.1038/ni1547 · Cited by 368
Pradeepa, M. M., Sutherland, H. G., Ule, J., Grimes, G. R., & Bickmore, W. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002717 · Cited by 349
The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.
Kozmik, Z., Wang, S., Dörfler, P., Adams, B., & Busslinger, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2662 · Cited by 325
Genomics in acute lymphoblastic leukaemia: insights and treatment implications
Roberts, K. G., & Mullighan, C. G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.38 · Cited by 287
Änkö, M.-L., Müller-McNicoll, M., Brandl, H., Curk, T., Gorup, C., Henry, I., Ule, J., & Neugebauer, K. M. (2012) · Genome Biology · doi:10.1186/gb-2012-13-3-r17 · Cited by 277
Lynch, K. W., & Maniatis, T. (1996) · Genes & Development · doi:10.1101/gad.10.16.2089 · Cited by 237
Self-citationNicholson, I. C., Lenton, K. A., Little, D. J., Decorso, T., Lee, F. T., Scott, A. M., Zola, H., & Hohmann, A. W. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00144-2 · Cited by 226
Otero, D. C., Anzelon-Mills, A. N., & Rickert, R. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.73 · Cited by 160
HnRNP L represses exon splicing via a regulated exonic splicing silencer
Rothrock, C. R., House, A. E., & Lynch, K. W. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600745 · Cited by 152
Self-citationThe Physiologic Role of CD19 Cytoplasmic Tyrosines
Wang, Y., Brooks, S. R., Li, X., Anzelon-Mills, A. N., Rickert, R. C., & Carter, R. H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00426-0 · Cited by 144
Lynch, K. W., & Weiss, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.70-80.2000 · Cited by 144
Self-citationShoham, T., Rajapaksa, R., Kuo, C.-C., Haimovich, J., & Levy, S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1373-1385.2006 · Cited by 124
Chromatin and epigenetic regulation of pre-mRNA processing
Brown, S. J., Stoilov, P., & Xing, Y. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds353 · Cited by 113
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
Chung, E. Y., Psathas, J. N., Yu, D., Li, Y., Weiss, M. J., & Thomas‐Tikhonenko, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45851 · Cited by 112
Self-citationCD19 Function in Central and Peripheral B-Cell Development
Nagro, C. J. D., Otero, D. C., Anzelon-Mills, A. N., Omori, S. A., Kolla, R. V., & Rickert, R. C. (2005) · Immunologic Research · doi:10.1385/ir:31:2:119 · Cited by 105
CD19 Function in Early and Late B Cell Development. II. CD19 Facilitates the Pro-B/Pre-B Transition
Otero, D. C., & Rickert, R. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5921 · Cited by 94
Psathas, J. N., Doonan, P. J., Raman, P., Freedman, B. D., Minn, A. J., & Thomas‐Tikhonenko, A. (2013) · Blood · doi:10.1182/blood-2012-12-473090 · Cited by 82
Self-citationMyc overexpression brings out unexpected antiapoptotic effects of miR-34a
Sotillo, E., Laver, T., Mellert, H. S., Schelter, J. M., Cleary, M. A., McMahon, S. B., & Thomas‐Tikhonenko, A. (2011) · Oncogene · doi:10.1038/onc.2010.634 · Cited by 82
Self-citationWhere splicing joins chromatin
Hnilicová, J., & Staněk, D. (2011) · Nucleus · doi:10.4161/nucl.2.3.15876 · Cited by 75
Yu, D., Allman, D. A., Goldschmidt, M. H., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1797 · Cited by 63
Self-citationBarrett, D. M., Seif, A. E., Carpenito, C., Teachey, D. T., Fish, J. D., June, C. H., Grupp, S. A., & Reid, G. S. D. (2011) · Blood · doi:10.1182/blood-2011-04-346528 · Cited by 62
Self-citationChromatin’s thread to alternative splicing regulation
Iannone, C., & Valcárcel, J. (2013) · Chromosoma · doi:10.1007/s00412-013-0425-x · Cited by 53
Signal- and Development-Dependent Alternative Splicing of LEF1 in T Cells Is Controlled by CELF2
Mallory, M. J., Jackson, J., Weber, B., Chi, A., Heyd, F., & Lynch, K. W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05170-11 · Cited by 50
Self-citationTargeting the B-cell receptor signaling pathway in B lymphoid malignancies
Buchner, M., & Müschen, M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000048 · Cited by 45
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling
Cozma, D., Yu, D., Hodawadekar, S., Azvolinsky, A., Grande, S. M., Tobias, J. W., Metzgar, M. H., Paterson, J. C., Erikson, J., Marafioti, T., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30842 · Cited by 45
Self-citationAVISPA: a web tool for the prediction and analysis of alternative splicing
Barash, Y., Vaquero-Garcia, J., González‐Vallinas, J., Xiong, H. Y., Gao, W., Lee, L. J., & Frey, B. J. (2013) · Genome biology · doi:10.1186/gb-2013-14-10-r114 · Cited by 45
Self-citationIn silico to in vivo splicing analysis using splicing code models
Gazzara, M. R., Vaquero-Garcia, J., Lynch, K. W., & Barash, Y. (2013) · Methods · doi:10.1016/j.ymeth.2013.11.006 · Cited by 16
Self-citation
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“…that the epitope in the CD19 protein sequence that is recognized by the CAR can be selectively deleted at pro- 716 Cell 168, February 9, 2017 gression (Ruella et al., 2016) and that preexisting alternatively spliced CD19 isoforms might predispose to acquired resistance (Sotillo et al., 2015).”
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Metadata
- Authors
- Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., Martinez, N. M., Harrington, C. T., Chung, E. Y., Perazzelli, J., Hofmann, T. J., Maude, S. L., Raman, P., Barrera, A., Gill, S., Lacey, S. F., Melenhorst, J. J., Allman, D., Jacoby, E., Fry, T., Mackall, C., Barash, Y., Lynch, K. W., Maris, J. M., Grupp, S. A., & Thomas-Tikhonenko, A.
- Venue
- Cancer Discovery
- Published
- 2015-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 1282-1295
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2179454156
- Cited by
- 1,254
- References
- 47
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.